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Abstract
Background: Platelet-rich plasma (PRP) is a concentrate of autologous blood growth factors which has been shown to
provide some symptomatic relief in early osteoarthritis (OA) of the knee. The objective of this study was to test the
feasibility and efficacy potential of platelet rich plasma (PRP) in primary care.
Methods: Feasibility study to assess safety of the intervention procedures and assess primary and secondary outcome
measures. Consecutive patients presenting with symptomatic knee OA were recruited in a primary care setting in
Ireland. All participants received three injections of PRP 4 weeks apart. The following self-reported clinical outcomes
were evaluated before and after therapy (4 months): Pain and disability (ICOAP questionnaire); health utility (EUROQol);
adverse events; patient satisfaction and goal-orientated outcomes.
Results: Seventeen potential patients were identified of whom 14 were eligible to participate. Twelve consented and
completed the intervention and all outcome measures. There were no losses to follow-up. One patient reported pain
and stiffness for 2 days after the first injection but did complete the study. No growth was detected from nine
consecutive samples sent for microbiology analysis. Changes in constant, intermittent and total pain scores
were reported; pain fully resolved in two patients. In addition, health utility, patient satisfaction and goal-orientated
outcomes also demonstrated improvement.
Conclusions: Platelet-rich plasma therapy is a simple and minimally invasive intervention which is feasible to deliver in
primary care to treat osteoarthritis of the knee joint. Well-designed randomised controlled trials are needed to measure
outcomes, durability of effect and cost effectiveness.
Keywords: Chronic disease, Musculoskeletal/connective tissue disorders, Orthopaedics, Therapeutic injection, Osteoarthritis
of the knee, Community medicine, Managed care
Key messages
 Platelet-rich plasma (PRP) is a concentrate of
autologous blood growth factors.
 PRP has been shown to provide some symptomatic
relief in knee osteoarthritis.
 To date, this intervention has been largely delivered
in hospital settings.
 This study has shown that it is feasible to deliver PRP
therapy in primary care.
 This therapy appears to have minimal associated
adverse events.
 This therapy appears to be associated with
improvements in patient outcomes.
Background
Osteoarthritis (OA) is a leading cause of disability and
doubles the number of visits to primary care practi-
tioners for those with the condition in comparison to
those without [1]. OA affects the knee more often than
any other joint [2]. With the ageing of the population
and the growing obesity epidemic, the number of surgi-
cal procedures for knee OA will increase dramatically in
the coming years, of which knee replacement is the most
costly to the health care system and burdensome for the
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patient. Other treatment options for OA of the knee
would be of great value.
The joint destruction arising from OA occurs as a re-
sult of an imbalance in the equilibrium between the
breakdown and repair of the joint tissue while a combin-
ation of cellular changes and biomechanical stresses
causes several secondary changes in the joint itself.
Recent research has identified a number of key biochem-
ical pathways that could be targeted therapeutically
through biological intervention [3]. Platelet-rich plasma
(PRP) is one such intervention. PRP is an autologous
concentration of human platelets in a small volume of
plasma, where the platelet concentration is higher (typic-
ally up to five times higher) than the normal platelet
concentration in a healthy person’s blood. Emerging evi-
dence suggests PRP has the potential to have a regenera-
tive effect on certain body tissues, in addition to the
main role platelets play in haemostasis [4]. PRP has been
shown to provide some symptomatic relief in early OA
of the knee and to be at least as effective as intra-
articular hyaluronic acid and steroid injections for symp-
tom control [5]. This therapy is a minimally invasive
intervention which could be used to enhance tissue re-
generation. PRP contains alpha granules, in which about
70% of their growth factors will be secreted in the first
10 min, and almost all the stored amount will be re-
leased in the first hour [6]. These growth factors activate
some of the cells which are responsible for tissue healing
and bone and cartilage regeneration [7]. As PRP is an
autologous blood product, there is no risk of immuno-
logical reactions and disease transfer, but as with any in-
jection procedure, there will be some possibility of a
local anaesthesia reaction, infection and bleeding [8].
The current study is designed to better understand
this new therapy and to see if it is feasible to carry
out this therapy in primary care in order to poten-
tially avoid expensive hospital visits and interven-
tions such as joint replacement. Current NICE
guidelines confirm that PRP injections for knee
osteoarthritis raise no major safety concerns, but the
evidence on efficacy is inadequate and requires fur-
ther research [9]. The aim of this study is to test the
feasibility and efficacy potential of platelet-rich
plasma (PRP) in primary care to treat degenerative
lesion of articular cartilage of the knee in order to
prepare for a phase II pilot randomised controlled
trial of this intervention in primary care according
to the Medical Research Council evaluation frame-
work [10]. The specific objectives were to determine
(1) trial feasibility, including recruitment, retention
and assessment of outcome measures and (2) inter-
vention feasibility, including intervention fidelity, at-
tendance, acceptability to participants and potential
of primary care to deliver the intervention.
Methods
Participants and setting
This study took place in the West of Ireland, and partici-
pants were recruited and followed up through the North
Clare Primary Care Team, a rural-based primary care
team covering an economically diverse but predomin-
antly Caucasian population of approximately 8000 indi-
viduals [11]. Consecutive patients presenting to primary
care with acute symptoms on a background of at least a
3-month history of chronic pain or swelling of the knee
with radiologically confirmed (X-ray or MRI) osteoarth-
ritis of the knee joint were screened for inclusion in the
study. The following exclusion criteria were applied: cog-
nitive impairment, acute mental or physical illness;
unstable medical conditions; under 18 years of age; preg-
nancy and breastfeeding; coagulation disorders; im-
munosuppression; pending legal action pertaining to
knee pain; cortisone injection within 6 weeks; use of
NSAIDS 1 week beforehand who were unwilling to stop
medication; inflammatory arthritis; previous infection of
the knee joint; knee surgery within 3 months; active in-
fection or malignancy; patients on Warfarin with an INR
> 3. At the first contact, information about the study was
provided to potential participants by their family doctor
and they were invited to attend a preliminary screening
meeting at their primary care centre with the study in-
vestigators. If eligible, informed consent was obtained
and participants were assigned a code. All participants
then completed a baseline assessment, including con-
firmation of diagnosis of knee arthritis and signed con-
sent. Baseline visit at their primary care centre was then
arranged at which they completed baseline question-
naires on outcome measures and then received their first
PRP treatment. The treatment protocol used was in line
with international best practice and consisted of three
injections separated by 4 weeks each. Follow-up out-
come measures were collected 4 weeks after the last
PRP treatment (Fig. 1).
Intervention
The preparation of the PRP begins by taking specific vol-
ume of autologous blood from the patient, through a syr-
inge containing an anticoagulant. This sample is then
centrifugated into two layers: an inferior layer containing
erythrocytes and a superior layer consisting plasma, in
which the platelet layer will be isolated and injected into
the patient’s knee under a sterile environment [6]. The
preparation of PRP for the study focussed on the following
key processes taking into account the latest European
Guidelines on the use of platelet-rich plasma [12]: Achiev-
ing a platelet concentration above baseline; use of anticoa-
gulation; and addition of exogenous activation. In
accordance with the guidelines, venepuncture, centrifuga-
tion and injection were all being carried out within a single
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procedure by a healthcare professional. No blood products
were frozen or stored. The centrifuge used in the procedure
was located in the same room as the procedure took place
and was not used for spinning any other samples during
the procedure.
Recommendations for the standardisation of the PRP
procedure have been well described and were carefully
adhered to in order to achieve appropriate platelet con-
centrations [13]. Fresh blood was drawn from the inter-
vention patient and prepared directly before each
injection of PRP. In order to check sterility, small vol-
umes (2.8 ml) of prepared PRP were sent for microbiol-
ogy testing to ensure complete sterility. Venipuncture
can result in contamination of collected blood [14]. To
provide confidence that such contamination had not oc-
curred, or that PRP had not become contaminated dur-
ing processing, microbiology analysis involved serial
dilution and incubation of samples aerobically and an-
aerobically at 37 °C on plate count agar, which is a
growth medium suitable for detection of skin-derived
microorganisms. Blood was drawn into a closed system
of anticoagulant vacutainer tubes containing 3.8% so-
dium citrate. Each tube contained a maximum volume
of 2.8 ml so eight tubes were drawn from each partici-
pant. This system has a needle of 21 gauge for vene-
puncture to minimise any platelet activation. These
tubes then underwent the first spin cycle in a Labofuge
200 ™ centrifuge manufactured by Heraeus and owned
and calibrated by the Clinical Research Facility Galway
(CRFG). This spin cycle was at 900g for 5 min. For this
machine, this translates as a speed of 2900 revolutions
per minute (rpm) based on the following calculation:
g = 1.12 × radius of centrifuge × (rpm/1000)2. The tubes
were then removed from the centrifuge and the plasma
supernatant aspirated immediately (to prevent diffusion),
using sterile technique, into a closed sterile container for
the second spin which was at 1000g for 10 min. For this
machine, this translates as a speed of 3100 rpm based on
the same calculation given above.
After the second spin, the lower 1/3 of plasma contain-
ing the concentrated platelet solution was aspirated again
using sterile technique, into a closed system containing
10% Ca-chloride (Ca2+ = 0.22 mEq) for platelet activation.
The final volume for injection was 4–5 ml. All injections
were performed by the same physician (LG) who had
received training in and been carrying out knee
arthrocentesis as part of routine clinical practice. Having
prepared the skin of the participant with iodine solution
and using a ‘no touch’ aseptic technique, the activated
PRP was injected into the knee joint using a superomedial
approach. Ethinyl chloride spray was applied to the skin
just prior to injection to provide topical anaesthesia.
Outcome measures
We piloted the planned outcome measures to be used in
the main trial, to ensure that they were acceptable and
comprehensible to patient, and that our methods of ad-
ministration were feasible and reliable. Self-reported
clinical outcomes were evaluated before and after ther-
apy (4 months). All self-report measures used were in
previously validated formats. The primary and secondary
outcome measures were chosen in accordance with
OMERACT guidelines and were the following: Constant,
intermittent and total pain scores were measured using
the ICOAP questionnaire for knee arthritis; health utility
was measured using EUROQol (EQ-5D-3L and EQ-VAS);
complications and all adverse events were measured using
adverse event forms at 8 and 16 weeks; overall patient
Fig. 1 Flow diagram of the study
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satisfaction was measured using a Likert scale from 1 to 5
where 1 is very dissatisfied and 5 is very satisfied; and
finally, we elicited patient goal-orientated outcomes. This
final outcome measure was chosen as in a disease such as
OA which more often than not exists in the context of
multimorbidity; we felt it was particularly important to
ask patients what they wanted from the intervention
rather than concentrate only on established and vali-
dated outcome measures [15]. Patients were asked to
describe their goals and also whether these goals had
been achieved at follow-up (Not achieved, Partially
achieved, Fully achieved).
Statistical analysis
A formal sample size for this feasibility study was not
calculated [16]. Baseline data was summarised using
suitable numerical summaries and graphical techniques.
Adverse events were reported individually at each time
point. The EQ-5D-3L index value for health status was
calculated for each patient with reference to a general
population survey from the UK [17]. The distribution of
changes from baseline to follow-up for each numeric
outcome variable was tested for normality, and paired
samples t tests were used for normally distributed
changes. Mean changes with 95% confidence intervals
(CI) are reported. A 5% level of significance was used for
all tests. All statistical analyses were performed using the
software package SPSS (version 24.0).
Results
Recruitment and baseline characteristics of trial participants
Of the 17 patients screened for the study, 14 were
eligible to participate and 12 of these agreed to par-
ticipate and were consented (Fig. 1). Of the three
patients who were not eligible to participate, two
had a cortisone injection within 6 weeks and one
had inflammatory arthritis. The 12 participants that
were eligible and consented had a mean age (SD) of
72.6 (10.4) years and mean BMI (SD) of 31.8 (4.6),
and seven (58%) were male. Other baseline clinical
characteristics are described in Table 1. Goal-
orientated outcomes were identified by 92% (11/12)
of the group. Of this group, the most common goal
defined was to be pain free (6/12), followed by walk-
ing normally without aid (2/12). Other goals in-
cluded decreasing knee stiffness (1/12), prevention of
knee replacement (1/12) and being able to dance
and garden again (1/12). The flow chart in Fig. 1
represents the movement of participants through the
stages of the study. Of the 12 participants that were
eligible and consented, all completed the full study
protocol and follow-up at 4 months.
Outcome data
A total of 39 knee injections of PRP were carried out on
12 patients (One patient had both knees injected on
each occasion). No patients reported adverse events at
the time of injection. One patient (8%) had pain and
stiffness after the injection for 2 days which responded
to paracetamol. There were no other adverse events
noted at 8 or 16 weeks. There was no evidence of micro-
bial growth after 72 h incubation from the nine consecu-
tive samples tested. In terms of responder status, at the
end of 4 months, 58.3% (7/12) were very satisfied with
the procedure, 33.3% (4/12) were satisfied and one pa-
tient (8.3%) was not satisfied. This patient reported the
adverse event described above. In terms of goal-
orientated outcomes, 45.5% (5/11) felt they had fully
achieved their identified goal, 45.5% (5/11) felt they had
partially achieved their goal and 9% (1/11) felt they had
not achieved their goal either fully or partially. Again, it
was this patient that reported the adverse event de-
scribed above.
Baseline values, follow-up scores and change from
baseline to follow-up is summarised in Table 2 for con-
stant, intermittent and total pain scores. The reductions
in pain scores (95% CI) for total, constant and intermittent
pain were − 29.0 (− 39.1, − 18.9); − 28.8 (− 43.7, − 13.8);
and − 29.2 (− 41.5, − 16.8), respectively.
Table 1 Baseline characteristics of the participants (n = 12)
Baseline characteristics
Mean (SD); Range; Median
Age (years) 72.6 (10.4) years; 48–84 years; 73 years
Weight (kg) 89.3 (16.7) kg; 70-132 kg; 90 kg
∫Body mass index 31.8 (4.6); 25–42; 31.5
Number of patients (%)
Male gender 7 (58)
Female gender 5 (42)
∫Body mass index categories
BMI < 25 0 (0)
BMI 25–30 4 (33)
BMI > 30 8 (66)
#Medical card eligibility 10 (83)
Diagnosed by X-ray 10 (83)
Previous knee injury 8 (67)
Previous knee surgery 2 (17)
∫Body mass index is weight in kilogrammes divided by the square of the
height in metres
#Ireland does not have universal registration with a general practitioner.
Almost 45% of the population is registered through the Primary Care
Reimbursement Service (PCRS) (http://www.hse.ie/eng/staff/PCRS/) with the
remainder being described as private patients and able to see any general
practitioner. All patients aged over 80 years and those below defined income
levels (less than € 500 [£444] gross per week for a single person; € 900 [£798]
gross per week for a couple) are registered with the PCRS and are described as
‘Medical Card’ eligible
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At baseline, eight (67%) patients reported being in
constant pain (constant pain subscore > 0). This de-
creased to two patients reporting constant pain at
follow-up. All 12 patients had total pain and intermittent
pain scores greater than zero at baseline. Two patients
reported that their pain was fully resolved (total pain
score = 0) at follow-up.
Mean self-rating of health utility (EQ-VAS) increased
from baseline to follow-up (mean change 10.8, 95% CI 2.
5 to 19.2) (Table 2). Mean index values (EQ-5D-3L) also
increased from baseline to follow-up (mean change 0.32,
95% CI 0.18 to 0.46) (Table 2).
Discussion
Summary
This study has demonstrated that it is feasible and safe
to deliver PRP therapy in primary care for knee osteo-
arthritis. All patients completed the intervention and all
outcome measures. There were no losses to follow-up.
This therapy appears to be associated with significant
improvements in pain, health utility, patient satisfaction
and goal-orientated outcomes.
Comparison with existing literature
Pilot and prospective studies investigating the clinical ef-
ficacy of intra-articular injections of PRP in patients with
knee OA have demonstrated clinical improvement in
self-reported pain and functional capacity with no major
adverse effects [18]. In a recent related systematic re-
view, conducted by our research team, we included six
randomised controlled trials comparing the effectiveness
of PRP to other intra-articular injections, exercise or an-
algesia for a minimum of 6 months. PRP injections were
found to produce statistically significant improvements
in overall WOMAC scores for patients with knee osteo-
arthritis up to 12 months after intervention [19]. The
risk of adverse events in PRP-treated participants was
not significantly increased in comparison with other
knee osteoarthritis treatment options [19] These findings
are consistent with much recently published research in-
volving PRP as an intervention in knee OA [20]. The
goal-oriented outcome approach used in this study has
several advantages. It frames the discussion in terms of
individually desired rather than universally applied
health states; this approach simplifies decision making
for patients with multiple conditions by focusing on out-
comes that span conditions and aligning treatments
toward common goals; goal-oriented care prompts pa-
tients to articulate which health states are important to
them and their relative priority; and finally, if they know
what health states are most desired, patients and clini-
cians can agree on steps that can be taken to achieve
these goals and monitor progress in reaching them [15].
In essence, it allows the participant to co-design the out-
comes based on their own individual preferences.
Strengths and limitations
The strengths of this study are the clearly described
standard operating procedure, the high completion rate
for participants (100%) and the limited number of exclu-
sion criteria. The relatively small number of potential
participants that were excluded may help to facilitate
implementation particularly with such an open recruit-
ment strategy. However, this study also had a number of
limitations. It was a small feasibility study conducted in
a single country in a Caucasian population with short
follow-up and without a control group.
Implications for research and practice
The findings of our study are in keeping with other ex-
perimental studies of this nature [21, 22]; however, there
is heterogeneity across studies with regard to the severity
of the OA populations included, and the frequency, dose
and duration of PRP interventions. In addition, the long-
term outcomes of this form of therapy have not been
established, and the duration of the expected benefit of
PRP injections remains unclear, as most of the other
studies investigate the persistence of the desirable effects
up to 12 months post interventions but only a small
number of studies has a follow-up period beyond that.
Also, there is wide variety of PRP preparation protocols
across different studies, for example, in terms of total
number of absolute platelet and presence or absence of
white blood cells, so consensus about the standardisa-
tion of PRP is needed [23]. Patient choice seems also to
be an important factor as it has been shown that youn-
ger patients with earlier stage OA seem to be the most
responsive subgroup to treatment [24]. The number of
injections required is also not established with three in-
jections separated by 4 weeks each being the most com-
monly used protocol, but a previous study has shown
Table 2 Outcomes measures at baseline, follow-up (4 months)
and change from baseline (n = 12)
Outcome Baseline
Mean (SD)
and range
Follow-up
Mean (SD)
and range
Mean change from
baseline (95% CI)
*Total pain score 45.3 (17.38)
25.0–77.3
16.3 (17.28)
0–63.6
− 29.0 (− 39.1, − 18.9)
*Constant pain
subscore
35.0 (27.96)
0–75.0
6.3 (16.39)
0–55.0
− 28.8 (−43.7, − 13.8)
*Intermittent
pain subscore
53.8 (10.87)
41.7–79.2
24.7 (21.06)
0–70.8
− 29.2 (−41.5, − 16.8)
#EQ-5D-3L 0.45 (0.19)
0.08–0.62
0.77 (0.25)
0.08–1.00
+ 0.32 (0.18, 0.46)
#EQ-VAS 63.4 (9.10)
50–80
74.3 (17.72)
40–100
+ 10.8 (2.5, 19.2)
*A reduction in pain scores indicates improvement
#An increase in quality of life score indicates improvement
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that a single injection of PRP is as effective as two injec-
tions [3]. The next obvious steps following on from this
feasibility study are a phase II pilot randomised con-
trolled trial in primary care to assess feasibility of trial
methods followed by a full methodologically robust, ran-
domised controlled trial to determine the effectiveness
of this form of therapy, both for short- and long-term
outcomes. In addition, the experience of patients follow-
ing participation in this form of therapy warrants further
consideration through the use of qualitative methods.
Our findings have a number of tentative clinical impli-
cations. These should be contextualised in the limita-
tions of the study. Our results suggest that PRP is a safe
and feasible therapy that can be delivered in the primary
care setting. The arthrocentesis element of this interven-
tion does require training and experience but is already
within the scope of practice of many primary care physi-
cians. However, adequate resourcing will be required to
make this form of intervention widely available in pri-
mary care.
The main side-effect of PRP injection is pain at and
around the injection site. Current evidence suggests that
this pain is uncommon, responds to simple analgesics
and may last for a few days. Finally, all injections were
delivered by an experienced family doctor. However,
there is scope to explore the role of musculoskeletal
clinical specialist physiotherapists in the delivery of this
treatment approach.
Conclusions
Platelet-rich plasma therapy is a simple, low-cost and
minimally invasive intervention which is feasible to de-
liver in primary care to treat degenerative lesions of ar-
ticular cartilage of the knee. This therapy appears to
have minimal associated adverse events and may have
beneficial effects in terms of pain, health utility, patient
satisfaction and goal-orientated outcomes. Further stud-
ies, particularly well-designed randomised controlled tri-
als are needed to understand the mechanism of action,
establish best practice, and measure outcomes and dur-
ability of effect.
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